Tiger Brokers

AstraZeneca Collaborating With CSPC Pharma in siRNA Drug Deal Worth Up to $1.77 Billion

MT Newswires Live
Jul 02

AstraZeneca (AZN) has entered into a collaboration, option and license agreement with CSPC Pharmaceutical to develop small interfering RNA (siRNA) therapies targeting kidney diseases, CSPC said Thursday.

Under the agreement, the companies will jointly discover and develop preclinical candidates for two renal disease targets using CSPC's proprietary siRNA drug discovery and extrahepatic delivery platforms, it said.

AstraZeneca will have the option to secure exclusive global or ex-China development and commercialization rights for each program, while CSPC will retain China rights to one candidate, it added.

CSPC will receive a $30 million upfront payment and is eligible for up to $540 million in development milestones and up to $1.2 billion in sales milestones, plus single-digit royalties on annual net sales, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10